Daily Ards Research Analysis
Analyzed 15 papers and selected 3 impactful papers.
Summary
Analyzed 15 papers and selected 3 impactful articles.
Selected Articles
1. Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation in Preterm Infants With Respiratory Distress Syndrome: A Randomized Clinical Trial.
In a multicenter noninferiority RCT of 312 extremely preterm infants with RDS receiving early MISA, initial NIPPV halved NIV failure within 72 hours versus NCPAP and remained superior at 7 days, without excess complications. Early stopping on prespecified criteria supports robustness, but long-term outcomes remain to be assessed.
Impact: Provides high-quality randomized evidence clarifying initial NIV strategy in extremely preterm infants, demonstrating inferiority of NCPAP under an early MISA protocol.
Clinical Implications: For extremely preterm infants with RDS receiving early MISA, NIPPV should be preferred over NCPAP as initial respiratory support to reduce early intubation; clinicians should still monitor for long-term outcomes given early trial termination.
Key Findings
- NIV failure within 72 hours: 26.1% with NCPAP vs 13.2% with NIPPV; adjusted risk difference 12.8% (95% CI, 4.2%-21.6%; P=.004).
- NIV failure within 7 days: 27.5% with NCPAP vs 15.1% with NIPPV; risk difference 12.4% (95% CI, 3.4%-21.4%; P=.008).
- No significant between-group differences in major complications (e.g., pneumothorax, BPD).
- Trial stopped early at 312 of planned 960 based on prespecified O'Brien-Fleming criteria; registered (NCT05137340).
Methodological Strengths
- Multicenter randomized noninferiority design with prespecified stopping rules and trial registration.
- Clear primary endpoint with objective criteria (intubation within 72 hours) and consistent secondary outcomes.
Limitations
- Early termination may limit precision and assessment of longer-term outcomes.
- Open-label nature and setting limited to Chinese tertiary NICUs may affect generalizability.
Future Directions: Assess neurodevelopmental and respiratory outcomes beyond discharge, evaluate protocolized NIPPV settings, and replicate in diverse health systems.
IMPORTANCE: Respiratory distress syndrome (RDS) remains a leading cause of morbidity and mortality in preterm infants. Evidence regarding the optimal initial noninvasive ventilation (NIV) mode for extremely preterm infants (<30 weeks' gestation) with RDS is inconsistent. OBJECTIVE: To determine whether nasal continuous positive airway pressure (NCPAP) is noninferior to nasal intermittent positive pressure ventilation (NIPPV) as primary respiratory support before minimally invasive surfactant administration (MISA) for reducing intubation within 72 hours in preterm infants with RDS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, noninferiority randomized clinical trial was conducted across 11 tertiary neonatal intensive care units in China from December 2021 to October 2024. The trial was designed to enroll 960 infants but was stopped early after enrolling 312 (32.5% of the target) based on prespecified stopping criteria. The enrolled participants were spontaneously breathing preterm infants at 24 to 29+6 weeks' gestation with a diagnosis of RDS requiring noninvasive respiratory support after birth. Data were analyzed from January 7 to May 9, 2025. INTERVENTION: Infants were randomized 1:1 to receive NCPAP or NIPPV as initial respiratory support. All received MISA within 120 minutes after birth via a 1.67-mm catheter. MAIN OUTCOMES AND MEASURES: The primary outcome was NIV failure, defined as requiring intubation and invasive mechanical ventilation within 72 hours after birth. The noninferiority margin was set at a 10% risk difference. Secondary outcomes included NIV failure within 7 days, surfactant redosing, and major complications (eg, pneumothorax, bronchopulmonary dysplasia). RESULTS: A total of 312 preterm infants (median [IQR] gestational age, 28.0 [28.6-29.4] weeks; 174 boys [55.8%]) were randomized to the NCPAP group (153 infants) or the NIPPV group (159 infants). NIV failure within 72 hours occurred in 40 infants (26.1%) in the NCPAP group vs 21 infants (13.2%) in the NIPPV group (adjusted risk difference, 12.8%; 95% CI, 4.2%-21.6%; P = .004; O'Brien-Fleming adjusted α = .005), exceeding the noninferiority margin and conclusively demonstrating inferiority of NCPAP. NIV failure within 7 days was also higher in the NCPAP group (42 infants [27.5%] vs 24 infants [15.1%]; risk difference, 12.4%; 95% CI, 3.4%-21.4%; P = .008). No significant differences were observed between groups for most complications. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of preterm infants with RDS, NIPPV with MISA as initial respiratory support significantly reduced NIV failure within 72 hours compared with NCPAP. These findings suggest that NIPPV may be the preferred primary respiratory strategy for this high-risk population, although further evaluation of long-term outcomes is warranted due to early trial termination. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05137340.
2. Mavacamten alleviates sepsis-induced acute respiratory distress syndrome by modulating the PI3K/AKT/autophagy axis: a spatial transcriptomic-guided investigation.
Using spatial transcriptomics and computational screening, mavacamten was identified and validated as a repurposing candidate that improves survival and lung injury in a murine CLP-induced ARDS model by inhibiting PI3K/AKT signaling and restoring autophagy. The study integrates in vitro and in vivo validation with mechanistic insight.
Impact: Demonstrates a rigorous, mechanism-based repurposing approach for sepsis-induced ARDS, leveraging spatial transcriptomics to bridge discovery and preclinical validation.
Clinical Implications: While preclinical, results justify early-phase clinical evaluation of mavacamten for sepsis-induced ARDS, with biomarker-driven selection and monitoring of autophagy and PI3K/AKT activity.
Key Findings
- Spatial transcriptomics revealed sepsis-induced reorganization of lung cellular clusters.
- Mavacamten reduced LPS-induced inflammation, oxidative stress, and cell injury in vitro.
- In CLP mice, mavacamten improved 7-day survival, arterial oxygenation, and reduced pulmonary edema and histological injury.
- Mechanistically, mavacamten suppressed PI3K/AKT/mTOR activation and restored autophagy in lung tissue.
Methodological Strengths
- Integration of spatial transcriptomics with computational drug screening and multi-system validation (in vitro and in vivo).
- Mechanistic interrogation of PI3K/AKT/mTOR and autophagy pathways corroborated by functional outcomes.
Limitations
- Murine CLP model may not fully recapitulate human sepsis-induced ARDS heterogeneity.
- Potential off-target and cardiomyopathic effects of a myosin inhibitor require careful safety evaluation.
Future Directions: Conduct dose-finding and safety studies, identify pharmacodynamic biomarkers (autophagy, PI3K/AKT signaling), and stratify clinical trials by sepsis endotypes.
BACKGROUND: Sepsis-induced acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung condition with high mortality and no specific pharmacological treatments. The complex spatial heterogeneity of the lung during sepsis hinders the discovery of effective therapies. This study aimed to use spatial transcriptomics to map the septic lung's molecular landscape to identify and validate a novel therapeutic agent. METHODS: We performed spatial transcriptomics on lung tissues from mice subjected to cecal ligation and puncture (CLP) to model sepsis. A computational drug screen identified Mavacamten. In vitro, lipopolysaccharide-stimulated murine alveolar epithelial cells were used to assess Mavacamten's effects on inflammation and cell injury. In vivo, CLP mice received Mavacamten, and we assessed survival, lung function, pulmonary edema, histology, and inflammatory markers. The underlying mechanism was investigated by analyzing the PI3K/AKT/mTOR pathway and autophagy markers. Statistical analyses included ANOVA, t-tests, and Kaplan-Meier analysis. RESULTS: Spatial transcriptomics revealed distinct cellular clusters that were dramatically rearranged during sepsis. In vitro, Mavacamten significantly attenuated lipopolysaccharide-induced inflammation, cellular injury, and oxidative stress. In the CLP mouse model, Mavacamten treatment markedly improved 7-day survival, restored arterial oxygenation, reduced pulmonary edema, and lessened histological lung injury. Mavacamten also significantly lowered local and systemic pro-inflammatory cytokine levels. Mechanistically, Mavacamten reversed the sepsis-induced inhibition of autophagy and suppressed the activation of the PI3K/AKT/mTOR signaling pathway in lung tissues. CONCLUSIONS: Mavacamten confers robust protection against sepsis-induced ARDS in a preclinical model by mitigating inflammation and lung injury, leading to improved survival. Its therapeutic action is mediated by inhibiting the PI3K/AKT pathway and restoring protective autophagy. Mavacamten is a promising candidate for repurposing in the treatment of sepsis-induced ARDS.
3. Lung Superimposed Pressure in Pediatric Acute Respiratory Distress Syndrome: Single-Center Study, 2014-2024.
Quantitative CT in 12 pARDS cases versus 24 controls showed higher dorsal superimposed pressure in pARDS and correlations with chest circumference and lung weight, but no association with oxygenation indices. Findings suggest caution against PEEP titration based solely on oxygenation targets in pARDS.
Impact: Introduces pediatric-specific quantitative mechanics showing superimposed pressure heterogeneity and decoupling from oxygenation, challenging adult-derived PEEP titration paradigms.
Clinical Implications: PEEP titration in pARDS should consider patient size and lung mechanics beyond oxygenation; bedside strategies may integrate imaging surrogates or EIT where feasible.
Key Findings
- Dorsal superimposed pressure was higher in pARDS vs controls (median 5.9 vs 3.0 cm H2O; p<0.001) with ventral-to-dorsal gradient.
- pARDS lungs had higher weight, lower gas/tissue ratio, and less normally aerated tissue than controls.
- In pARDS, SP correlated with chest circumference (ρ=0.60; p=0.043) and lung weight (ρ=0.76; p=0.006), and inversely with normally aerated tissue (ρ=-0.72; p=0.011).
- No relationship was found between SP and oxygenation indices.
Methodological Strengths
- Quantitative CT analysis across 10 ventral-to-dorsal regions with age-matched controls.
- Correlation of SP with anthropometrics and lung tissue metrics adds mechanistic context.
Limitations
- Single-center retrospective design with small pARDS sample (n=12) limits generalizability.
- Lack of concurrent physiologic measurements (e.g., esophageal pressure) and outcomes linkage.
Future Directions: Prospective multi-center studies integrating bedside physiology (EIT, esophageal manometry) to validate SP-guided PEEP strategies in pARDS.
OBJECTIVES: Superimposed pressure (SP) is the hydrostatic pressure compressing dependent lung regions and is a major determinant of dorsal collapse in adult patients with acute respiratory distress syndrome (ARDS). CT studies clarify its role in determining the need for positive end-expiratory pressure (PEEP) in ARDS. We therefore aimed to describe SP in pediatric ARDS (pARDS) and assess its associations with anthropometric, clinical, and quantitative CT parameters. DESIGN: Retrospective cohort study. SETTING: Urban academic tertiary care children's hospital in Italy. PATIENTS: All children with pARDS undergoing noncontrast chest CT between 2014 and 2024 compared with age-matched control patients with normal lung findings undergoing chest CT. MEASUREMENTS AND MAIN RESULTS: We included 12 pARDS patients and 24 controls. Quantitative CT analysis was used to measure lung aeration and the SP in 10 ventral-to-dorsal regions. The median (interquartile range [IQR]) SP increased from ventral to dorsal in both groups but was higher in pARDS patients: (dorsal SP, 5.9 cm H2O [IQR, 4.4-7.5 cm H2O] vs. 3.0 cm H2O [IQR, 2.4-4.0 cm H2O]; p < 0.001). Compared with controls, we found that pARDS patients had higher lung weight, lower gas/tissue ratio, and less normally aerated tissue. In pARDS patients, SP correlated with chest circumference (ρ = 0.60; p = 0.043), lung weight (ρ = 0.76; p = 0.006) and inversely with normally aerated tissue (ρ = -0.72; p = 0.011). We failed to identify a relationship between SP and oxygenation indices. INTERVENTIONS: None. CONCLUSIONS: SP in pARDS is lower and more variable compared with descriptions in adult patients with ARDS and is both affected by disease severity and chest size. We failed to identify an association between oxygenation indices and SP, which raises concerns about titrating PEEP based on oxygenation targets alone. Further studies are needed to confirm and integrate these in pARDS.